Research article

Characterization of mixed lymphocyte reaction blocking antibodies (MLR-Bf) in human pregnancy
Manoj Kumar Pandey, Vijay Saxena and Suraksha Agrawal*

Address: Department of Medical Genetics, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Raebareli Road, Lucknow – 226014, (U.P.) India
Email: Manoj Kumar Pandey - manojpgi@yahoo.com; Vijay Saxena - vij90@hotmail.com; Suraksha Agrawal* - suraksha@sgpgi.ac.in
* Corresponding author

Abstract

Background: It is known that during normal pregnancy and after immunotherapy blocking antibodies are developed, these antibodies inhibit mixed lymphocyte reaction and are also anti-mitogenic in nature. Mixed lymphocyte reaction blocking antibodies are specific to the husband's lymphocytes. In the present study an attempt has been made to characterize the mixed lymphocyte reaction blocking antibodies in normal pregnancy and in women with recurrent spontaneous abortion after immunotherapy.

Methods: Serum was obtained from women of different gestational windows of pregnancy (Ist, IInd, IIIrd trimesters and post delivery period of normal pregnancy), recurrent spontaneous aborters from pre and post immunization. Healthy (male and females) controls were screened for the presence of mixed lymphocyte reaction blocking antibodies. The standard mixed lymphocyte reaction technique was used to evaluate the inhibitory effect of serum in the mixed lymphocyte reaction. Each serum was tested for cytotoxic antibodies. Immunoglobulin G and its isotypes were isolated according to the standard protocol.

Results: In the present study we have observed that there was significant inhibition of proliferation response when immunoglobulin G from different trimesters of pregnancy were added to one way mixed lymphocyte reaction or to phytohemagglutinin activated lymphocyte proliferation assay. Similar pattern was seen when immunoglobulin G isolated from adequately immunized women with recurrent spontaneous abortion was used. It was further confirmed that amongst all the isotypes of immunoglobulin G, only immunoglobulin G-3 was found to be positive for the inhibitory effect.

Conclusions: Present study indicates that mixed lymphocyte reaction blocking antibodies are immunoglobulin G-3 in nature. It is developed during pregnancy and also after immunotherapy in women with recurrent spontaneous abortion who subsequently have the successful pregnancy.

Background

Recurrent spontaneous abortion (RSA) is defined as the loss of three or more consecutive pregnancies prior to 20 weeks of gestation. In a large number of patients the underlying cause of pregnancy loss often remains unclear [1,2]. This may be due to anatomical uterine defects, chromosomal defects, parental chromosomal rearrangements, gene mutations, endocrine factors, sub clinical infections, environmental toxins, collagen vascular diseases, auto immune factors, and psychological trauma or stress. However, in most of the women (1% – 2%) who experience recurrent miscarriage, no cause can be identified.
Alloimmune mechanisms that prevent mothers from developing immunological responses essential for the survival of the semiallogeneic pregnancy have been proposed as the cause of 50% of all such losses. The maternal recognition of paternally derived foetal antigens has been well documented [3], and the presence of circulating antipaternal antibodies provides unequivocal evidence of a maternal immune response to the allogenic pregnancy. In contrast to allograft transplantation, paternal histocompatibility antigens expressed on the placenta elicit only limited T cell immuno-reactivity [4]. The immunoglobulins (IgGs) generated during pregnancy have been characterized as asymmetrically glycosylated antibodies [5–7].

We have reported in our earlier studies that significant levels of mixed lymphocyte reaction blocking antibodies (MLR-Bf) production by paternal lymphocytes immunization in women with RSA, leads to successful pregnancy [8]. In the present study an attempt has been made to characterize the MLR-Bf in the total IgG fraction from different gestational windows of pregnancy and also in RSA patients before and after immunization against their husband’s lymphocytes.

Methods
Serum samples were obtained from individuals of different groups (Table 1). All individuals gave their consent to participate in the study, and the protocol followed was approved by the institutes ethical committee. These groups included 40 women of different stages of pregnancy (10 each in Ist, IInd, IIIrd trimesters and post delivery period), 20 women with RSA (10 each of pre and post immunization), 10 healthy males and 10 unmarried non-pregnant females. All participants were screened for the presence of MLR-Bf. Serum samples were separated from non heparinized peripheral blood under aseptic conditions further these samples were heat inactivated. After heat inactivation each serum sample was aliquoted. One aliquot was added to a panel of three peripheral blood lymphocytes (PBL) activated by PHA (phytohemagglutinin). A second aliquot was added to one way mixed lymphocyte reaction (MLR). The dilution factor used was 50% volume by volume.

**Immunological parameters**
Peripheral blood lymphocytes were prepared by density gradient centrifugation on ficoll-hypaque. For isolation of T cells, PBL were incubated in plastic dishes at 37°C, 5% CO₂ for 12 hrs then passed through nylon wool columns. Responders and stimulators from unrelated individuals were chosen so that there was at least one human leukocyte antigen (HLA) class I and one HLA DR antigen mismatch was found between them. Irradiated stimulator cells (2800 rads) were cultured in round bottomed 96 well plates with the responder cell in a ratio of 1:1 and a concentration of 10⁶ cells/ml. Plates were kept at 37°C in a 5% CO₂ atmosphere. Proliferation was measured at day 5 with (H3) thymidine incorporation in the last 18 hrs before harvesting. The percentage (%) of inhibition was calculated by the following formula:

\[
\text{% Inhibition} = 1 - \frac{\text{Cpm in test MLR}}{\text{Cpm in control MLR}} \times 100
\]

Cpm = count per minute

MLR = mixed lymphocyte reaction

**Cytotoxic antibody determination**
The percentage of panel reactive antibodies (PRA) was evaluated against a panel of 50 individuals at room temperature using the standard NIH lymphocytotoxicity test. Sera were also tested on autologous cells to determine auto reactivity, and pretreated with dithiothreitol to dif-
ferentiate IgG from IgM mediated cytotoxicity. A standard micro lymphocytotoxicity test was used to determine cytoxicity against specific target cells. These cells were same which were used as stimulators in the MLR or in the PHA stimulation test. The same method was used to determine presence of cytotoxic antibodies in pooled IgG and its isotypes using its dilution up to the 1: 8 from its original concentration (10 mg/ml) in each test. If the sera contained lymphocytotoxic antibodies these antibodies were absorbed by using platelets.

**Isolation and purification of IgG and its isotypes from patient's sera**

10 individuals each from 1st, 2nd and 3rd trimester, post delivery and post immunotherapy were taken from those subjects who were positive for MLR-Bf activity. Each serum was centrifuged for 20 min at 10,000 × g. An ammonium sulphate saturated solution was added to the serum (60%w/v) and incubated for 2 hrs so that IgG was completely precipitated. After centrifugation for 20 min at 10,000 × g the pellet was resuspended in ammonium bicarbonate buffer and dialyzed against the same buffer. The serum was separated and purification of IgG was carried out. IgG was also isolated from 10 males, 10 women with RSA and 10 unmarried non-pregnant females (who had no MLR-Bf activity). IgG fraction was prepared independently from each individual. Dialyzed product was fractionated on protein A coupled cyanogen bromide activated sepharose 4B columns.

Purity of the preparations was assessed by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) with standard molecular weight marker and purified human IgG as well as enzyme linked immunosorbant assay (ELISA) by using monoclonal antibodies directed against IgG. Further all the isotypes of IgG (IgG1, IgG2, IgG3 and IgG4) were separated on a protein A coupled cyanogen bromide activated sepharose 4B columns. ELISA was used to detect the IgG isotypes in each peak. Monoclonal antibodies directed against IgG1, IgG2, IgG3 and IgG4 were used in each ELISA. Each IgG fraction was lyophilized and the protein content was measured.

**Statistical tests**

Results were expressed as median and interquartile range (IQR). To compare proliferation indices between different groups, the Mann-Whitney test was employed as the sample size was small in each group. However data from individual experiments were measured by analysis of variance (ANOVA) and Bonferroni’s multiple comparison test. A value of p < 0.05 was considered as statistically significant.

### Results

**Effect of neat serum on Lymphocytes**

To evaluate the inhibitory effect of serum we carried out some independent experiments with each serum from different groups as mentioned in the material methods section. Serum was added at 0 hr of culture. All the serum samples which inhibited the peripheral blood lymphocytes proliferation in primary MLR were considered as MLR-Bf positive serum. The significance of inhibition of the mixed lymphocytes reaction was compared with normal pooled AB (non cytotoxic) serum. The differences were statistically significant (P < 0.001).

On the basis of this inhibitory mechanism, we further investigated the effect of these sera on PHA stimulated cells of the person's own PBL and unrelated PBL separated from three normal male controls. These were also used as stimulators in the MLR assay. All the sera having inhibitory activity inhibited unrelated PBL responses (2456 ± 250 cpm) but failed to inhibit their own cellular response to PHA (30, 462 ± 1562 cpm). This indicated that inhibitory effect was not against the autologous cells.

Further, to examine the inhibitory effect of purified IgG we treated half of the stimulator cells with the inhibitory IgG for 4 hrs at 4°C and washed the cells for three times, mixed with untreated homologous stimulator PBL cells before using them in MLR. Pre incubated stimulator cells with the patient's sera were added to fresh stimulator PBL cells in the ratio of 1: 1 in MLR cultures. Under these conditions, values of (H3) thymidine uptake after 50/50 mix of pre-incubated and freshly isolated stimulator cells (3250 ± 3217 cpm) were not different from normal controls (33617 ± 2527 cpm, p > 0.05). In another set of experiments, after the addition of cells, harvesting was carried out at 2nd and 4th day from the primary MLR cultures to allogenic T cell lines, the allogenic cell proliferation were 21973 ± 1819 cpm and 20521 ± 2017 cpm. These results indicated that the inhibition of proliferation in MLR by women's sera is not due to the generation of suppressor cells.

**Determination of the inhibitory fraction in the sera of pregnant and post immunized women with RSA**

We further examined the blocking activity present in IgM and IgG fractions. The results of percent inhibition by women's sera (WS) IgG and IgM on primed and unprimed cell proliferation to alloantigens and PHA was analyzed. WS IgG inhibited autologous cell proliferation in the MLR system by 68.3 ± 3.19%. Inhibition was found when we used WS to check the third party proliferation (59 ± 3.08%) but to a lesser extent and failed to inhibit autologous cell proliferation (3.6 ± 4.16%). Fresh PBL proliferation to PHA was inhibited by WS IgG to 61.3 ± 7.4%. WS IgM did not possess any inhibitory effect on
both MLR and PHA stimulations. These results revealed that the antimitogenic effect was present in the IgG and not in the IgM fraction. To further determine whether cytotoxic antibodies were responsible for the potent antimitogenic effect present in the sera, we compared the inhibitory effect before and after removal of lymphocytotoxic antibodies against HLA class I antigens by platelet absorption. These were removed from 5 WS, 3 from different trimesters of pregnancy and 2 from post immunized women with RSA. The platelet-adsorbed sera (AS) were tested independently on autologous proliferation to alloantigens from control (husband’s AS) stimulator cells. They were also tested on the same donor (AS) cellular proliferation to PHA.

**Inhibitory action of IgG and its isotypes on cell function**

IgG and its each isotype purified from pooled sera from 5 individuals were subjected to lymphocytotoxicity and blocking activity. Pooled IgG1, IgG2, IgG3 and IgG4 fractions contained significant lymphocytotoxic activity at a serial dilution of 1:64 (neat concentration 10 mg/ml) against a panel of 50 T cells and 50 B cells. It was observed that IgG1, IgG2 and IgG4 showed 50–80% cytotoxicity respectively. However, in IgG3 fraction it was only 3%. After determination of these lymphocytotoxicity. IgG1, IgG2, IgG3 and IgG4 were further individually tested for blocking activity.

When fractionated IgG and its isotypes (IgG1, IgG2, IgG3 and IgG4) from different stages of pregnancy (1st, 2nd and 3rd trimester and post delivery period) and RSA women (pre and post immunization) was added (10–50 µg/µl) at 0 hr of culture and measured its inhibitory activity against the base line data (results not shown). Our results (Table 2 and 3) revealed that PHA and MLR proliferation was significantly inhibited (F = 56.2, P < 0.001), in the presence of whole IgG and IgG3 separated from all the stages of pregnancy (1st, 2nd and 3rd trimester) and post immunized RSA women. No inhibition was found with the addition of IgG and its isotypes fractionated from pre immunized RSA women, normal male and normal unmarried non-pregnant females.

**Determination of antibody 2 and antibody 3 activity in the inhibitory IgG3 fraction**

Since IgG3 fraction did not contain significant cytotoxic reactivity but had a significant antimitogenic activity it was tested for its capacity either to block or to enhance the antibody I from IgG1, IgG2 and IgG4 fractions that contained antibody I reactivity. The addition of three serial dilutions of IgG3 did not change the lymphocytotoxic titters present in either IgG1, IgG2 or IgG4 fractions against a known panel of T and B cell targets (data not shown) which demonstrates absence of anti-idiotypic activity in the pooled IgG3 fraction.

**Discussion**

The present study was carried out to characterize the MLR-Bf present in normal pregnancy and also developed after immunotherapy. To test this we isolated IgG fractions from women having MLR-Bf in their sera (normal pregnancy) and from post immunized RSA women and added to the cells stimulated by PHA. The same sera were also added to one way MLR. Our initial results demonstrated that the proliferation of cells was significantly less in the presence of whole IgG and IgG3 separated from all the stages of pregnancy (1st, 2nd and 3rd trimester) and post immunized RSA women. No inhibition was found with the addition of IgG and its isotypes fractionated from pre immunized RSA women, normal male and normal unmarried non-pregnant females.

| Different group of subjects | Proportionate change in the SI of IgG and its isotypes in terms of interquartile range (IQR) |
|----------------------------|---------------------------------------------------------------------------------------------|
|                           | IgG   | IgG1   | IgG2   | IgG3   | IgG4   |
|----------------------------|-------|--------|--------|--------|--------|
| 1st trimester              | 25(14–27) | 76(24–80) | 68(42–82) | 9(7–22) | 47(28–69) |
| 2nd trimester              | 29(11–31) | 82(44–84) | 51(39–68) | 7(6–34) | 79(65–92) |
| 3rd trimester              | 35(17–38) | 68(37–79) | 69(57–82) | 11(5–33) | 71(38–102) |
| Post delivery period       | 42(11–45) | 57(39–61) | 47(37–61) | 41(23–57) | 54(46–81) |
| Pre immunized RSA Women    | 38(28–56) | 43(26–63) | 64(29–71) | 37(26–69) | 66(33–87) |
| Post immunized RSA Women   | 21(19–28) | 62(49–83) | 72(39–77) | 8(5–24) | 52(37–69) |
| Healthy male               | 52(46–71) | 57(39–69) | 48(34–56) | 61(46–71) | 41(39–58) |
| Unmarried females          | 83(39–86) | 54(49–67) | 65(43–73) | 49(40–78) | 61(43–99) |

Values given in the table are calculated as stimulation index (SI) against the base line measurement and shown as median and interquartile range (IQR), n = 10. * P < 0.001.
PIBF has been shown to influence the balance of Th1-Th2 cells by a progesterone induced blocking factor (PIBF) have demonstrated the indication of asymmetric IgG synthesis of T helper 1 (Th1) cells to T helper 2 (Th2) cells play an important role in immune modulation. Other studies show that blocking activity is targeted to the unprimed T cell response, which is due to alloantigens. The antiimmunogenic effect is most likely due to the binding with foreign HLA class II antigens present on cells.

However, it is difficult to ascertain the exact site of action of the inhibitory IgG fraction. These antibodies are very likely synthesized systemically and act at the local level (placenta), blocking placental antigens and preventing immunological attack by maternal natural killer cells and cytotoxic lymphocytes. It has been reported that women with RSA had significantly lower levels of asymmetric IgG as compared to controls [9,10]. These antibodies show suppressive mechanism hence may be of the same nature as the blocking antibodies. It has been shown by a number of investigators that MLR-Bf is present during normal pregnancy while it is absent or very low in women with RSA [11–13]. It is argued that these factors may play a protective role perhaps by blocking the damaging effect of maternal lymphocytes.

Some investigators have questioned the role of blocking antibodies in the maintenance of normal pregnancy [14,15]. Their studies suggested that alterations in the ratio of Th helper 1 (Th1) cells to Th helper 2 (Th2) cells play an important role in immune modulation. Other studies have demonstrated the indication of asymmetric IgG synthesis by a progesterone induced blocking factor (PIBF) [16]. PIBF has been shown to influence the balance of Th1 cells to Th 2 cells which subsequently alters cytokine ratios and decrease the cell mediated immune response during pregnancy [17]. Thus the production of PIBF early in pregnancy may play a role in activation of cellular and humoral immune system to prevent the immunologic attack. However, the exact role is still controversial.

Tamura et al. [11] have reported that the presence of MLR-Bf during the 1st pregnancy makes a significant contribution in the success of 2nd pregnancy. Ramhorst et al. [12] have shown that the blocking factor plays an important role in women with RSA undergoing immunotherapy. We recently demonstrated that MLR-Bf developed with the husband’s lymphocytes, during pregnancy and post immunotherapy in RSA women, is important for the success of human pregnancy [8]. Gatenby [18] have reported that development of MLR-Bf might be because of prolonged maintenance of CD8+ suppressor T cells, which suppress the immune mechanisms that are required for the maintenance and the outcome of successful pregnancy. Our results definitely show that the presence of MLR-Bf during pregnancy and after immunotherapy is a good prognostic marker for the success of pregnancy. The success of pregnancy in the face of potential maternal immune reactions has been largely attributed to the placenta, which appears to serve as an immunological barrier. The ability of the trophoblast tissue to succeed in the conditions of allograft rejection was initially attributed to the non-antigenic nature. But later it was shown that the trophoblast expresses major histocompatibility complex (MHC) antigens on the surface[19]. This can lead to alloantibody formation during normal pregnancy. Alloimmunity has been indicated.

Table 3: Percentage inhibition (%) of MLR-Bf significant IgG and its isotypes

| Different group of subjects | IgG | IgG1 | IgG2 | IgG3 | IgG4 |
|-----------------------------|-----|------|------|------|------|
|                            | W × H (1:2) | H × W (2:1) | W × H (1:2) | H × W (2:1) | W × H (1:2) | H × W (2:1) | W × H (1:2) | H × W (2:1) |
| 1st trimester               | 39 (35–67) | 26 (21–63) | 22 (18–28) | 24 (15–26) | 17 (11–37) | 21 (7–42) | 68 (61–68) | 64 (60–63) | 19 (17–45) | 17 (11–21) |
| 2nd trimester              | 42 (28–71) | 39 (35–64) | 18 (15–24) | 17 (14–19) | 12 (3–33) | 11 (9–15) | 61 (63–70) | 62 (61–67) | 29 (14–33) | 4 (17–8) |
| 3rd trimester              | 27 (21–62) | 35 (27–67) | -14 (27–9) | 13 (8–27) | 15 (9–23) | 17 (14–21) | 67 (61–82) | 71 (62–76) | 15 (15–28) | 13 (9–16) |
| Post delivery period       | 44 (20–68) | 25 (23–68) | 17 (3–20) | 15 (10–30) | 5 (9–19) | 11 (7–31) | 47 (14–47) | 41 (23–52) | 8 (4–17) | 11 (6–22) |
| Pre immunized RSA Women    | 34 (28–47) | 28 (23–61) | 6 (12–9) | 6 (11–2) | 2 (24–11) | 5 (22–7) | 43 (17–37) | 38 (21–36) | 6 (12–6) | 8 (5–19) |
| Post immunized RSA Women   | 51 (44–69) | 60 (57–73) | -7 (16–7) | 4 (12–6) | 12 (6–31) | 21 (11–29) | 67 (64–82) | 67 (62–71) | 21 (19–26) | 15 (10–30) |
| Healthy male males         | -9 (21–2) | -17 (8–4) | -17 (19–2) | -8 (11–3) | -15 (27–5) | 4 (17–2) | -11 (19–9) | -12 (18–7) | -6 (29–4) | -11 (18–19) |
| Unmarried females          | -17 (24–6) | -23 (35–2) | -7 (11–3) | 3 (7–10) | -5 (17–4) | 9 (21–12) | 15 (11–3) | 12 (6–17) | 14 (11–22) | 25 (24–27) |

I:2 (non irradiated cells of control female × irradiated cells of control male), 2:1 (non irradiated cells of control male × irradiated cells of control female) W = wife, H = husband. Values given in the table are calculated as percentage inhibition (%) against the base line measurement and shown as median and interquartile range(IQR), n = 10.**P < 0.001
in several studies by the association of habitual abortion with an increased sharing of human leukocyte antigens that may prohibit the mother from making blocking antibodies [20,21].

Our results indicated that a significant amount of MLR-Bf developed during pregnancy and after paternal lymphocyte immunotherapy in women with RSA is of IgG 3 nature, which may play an important role in the success of pregnancy in these women. Zennclussen et al. [10] have demonstrated that women undergoing immunotherapy expressed higher percentage of asymmetric IgG antibodies, which play a protective role during pregnancy.

It has been observed that inhibition of T cell activation is caused by the antibodies against the α-3 domain of the human MHC class I molecule. Stach and Rowley [22] have demonstrated that the inhibitory fraction is associated with transforming growth factor-beta (TGF-β). They have suggested that immunoglobulin – TGF-β conjugate is taken up by the antigen presenting cells by FC dependent mechanisms. It is conceivable that the inhibitory IgG preparations employed in our study contain antibody – cytokine conjugates that target and are internalized by antigen presenting cells following binding to MHC encoded public epitopes of class I or II molecules expressed on the allogenic cells. It may be postulated that absence of these inhibitory antibodies in women with RSA may prevent the generation of suppressor systems, which are required for the survival of the foetus as an allograft.

Conclusion
Our results clearly demonstrated that MLR-Bf in the shape of IgG3 fraction was generated during pregnancy but absent in women with RSA, unmarried non-pregnant females and normal healthy males. Upon immunotherapy this fraction (IgG3) was also developed in women with RSA and played an important role in the maintenance of pregnancy.

Competing interests
This study was supported by a research grant-in-aid from the Indian Council of Medical Research (ICMR), Govt. of India. We would like to pay thanks to Mr. Sanjay Kumar Johari for his computer assistance.

Authors’ Contributions
MKP drafted and planned the study, carried out all the experiments and statistical analysis. VS did the sequence alignment. SA conceived the study and participated in its design and coordination.

References
1. Stephenson MD Frequency of factors associated with habitual abortion in 197 couples. *Fertil Steril* 1996, 66:24-29
2. Hassold T, Abruzzo M, Adkins K, Griffin D, Merritt M, Millie E, Saker D, Shen J and Zaragoza M Human aneuploidy: incidence, origin and aetiology. *Environ Mutagen* 1996, 28:167-175
3. Beer AE Immunopathologic factors contributing to recurrent spontaneous abortions in humans. *Am J Reprod Immunol* 1983, 4:182-184
4. Rodger JC Lack of a requirement for a maternal humoral immune response to establish or maintain successful allogeneic pregnancy. *Transplantation* 1985, 40(4):372-377
5. Chaoouat G, Voisin GA, Esclaler D and Robert P. Facilitation reaction (enhancing antibodies and suppressor cells) and rejection reaction (sensitized cells) from the mother to the paternal antigens of the conceptus. *Clin Exp Immunol* 1979, 35(1):13-24
6. Gentile T, Borel IM, Angelucci J, Miranda S and Margni RA Preferential synthesis of asymmetric antibodies in rats immunized with paternal particulate antigens. Effect on pregnancy. *J Reprod Immunol* 1992, 22:173-180
7. Kelemen K, Bognar I, Paul M and Szekeres-Bartho J. A progestrone-induced protein increases the synthesis of asymmetric antibodies. *Cell Immunol* 1996, 167:129-34
8. Agrawal S, Pandey MK, Mandal SK, Mishra LC and Agrawal SS. Human immune response on allogeneic foetus in normal fertile women and recurrent aborters. *BMC Pregnancy and Childbirth* 2002, 26
9. Ehlen AC, Gercel-Taylor C, Shields LB, Sanfilippo JS, Nakajima ST and Taylor DD Alterations in humoral immune responses associated with recurrent pregnancy loss. *Fertil Steril* 2000, 73(2):305-313
10. Zennclussen AC, Gentile T, Kortebani G, Mazzolli A and Margni R. Asymmetric antibodies and pregnancy. *Am J Reprod Immunol* 2001, 45(5):289-294
11. Tamura M, Takakuwa K, Arakawa M, Yasuda M, Kazama Y and Tanaka K. Relationship between MLR blocking antibodies and the outcome of the third pregnancy in patients with two consecutive spontaneous abortions. *J Reprod Med* 1998, 26(1):49-53
12. Ramhorst R, Agriello E, Zittermann S, Pandio M, Larriba J, Irigoyen M, Cortelezar M, Auge L, Lombardi E, Etchepareborda JJ, Contreras Ortiz C and Fairboim L. Is the paternal mononuclear cells’ immunization a successful treatment for recurrent spontaneous abortion? *Am J Reprod Immunol* 2000, 44(3):129-135
13. Agrawal S, Pandey MK and Pandey A. Prevalence of MLR blocking antibodies before and after immunotherapy. *J Hematother Stem Cell Res* 2000, 9(2):257-262
14. Pope RM Immuno-regulatory mechanisms present in the maternal circulation during pregnancy. *Bailiere’s Clin Rheumatol* 1990, 4:333-351
15. Hill JA, Polgar K and Anderson D. The inhibition of T helper 1-type immunity to trophoblast in women with recurrent spontaneous abortion. *JAMA* 1995, 273(24):1933-1936
16. van der Velden W and Trefers FE Prognosis of subsequent pregnancies after recurrent spontaneous abortion in first trimester. *Br Med J Clin Res Ed* 1987, 295:92-93
17. Szekeres-Bartho J and Wegmann TG progestrone – dependent immunomodulatory protein alters the Th1/Th2 balance. *J Reprod Immunol* 1996, 31(1-2):81-95
18. Gateby PA, Moore H, Cameron K, Doran TJ and Adelstein S. Treatment of recurrent spontaneous abortion by immunization with paternal lymphocytes: correlates with outcome. *Am J Reprod Immunol* 1989, 19(1):27-31
19. Wegmann TG, Hossmann TR, Carlson GA, Oljnyk O and Singh B. The ability of the murine placenta to absorb monoclonal anti-fetal H-2K antibody from the maternal circulation. *J Immunol* 1979, 123(3):1020-1023
20. Beer AE, Semprini AE, Zhu XY and Quebemann JF Pregnancy outcome in human couples with recurrent spontaneous abortions: HLA antigen profiles; HLA antigen sharing; female serum MLR blocking factors and paternal leukocyte immunization. *Exp Clin Immunogenet* 1985, 2(3):137-153
21. Creus M, Balasch J, Fabregues F, Martorell J, Boada M, Penarrubia J, Barri PN and Vanrell JA. Parental human leukocyte antigens and implantation failure after in-vitro fertilization. *Hum Reprod* 1998, 13(1):39-43
22. Stach RM and Rowley DA. A first or dominant immunization II induced immunoglobulin carries transforming growth factor.
\( \beta \) and suppresses cytolytic T cell response to unrelated alloantigens. *J Exp Med* 1993, 178:835

**Pre-publication history**
The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1471-2393/3/2/prepub